



A Partial List of Recent Hematology/Oncology Fellow Publications

Telomerase-targeted therapies in myeloid malignancies.

Waksal JA, Bruedigam C, Komrokji RS, Jamieson CHM, Mascarenhas JO. Blood Adv. 2023 Aug 22;7(16):4302-4314. doi: 10.1182/bloodadvances.2023009903. PMID: 37216228

Novel therapeutics and targets in myelofibrosis.

Waksal JA, Harrison CN, Mascarenhas JO. Leuk Lymphoma. 2022 May;63(5):1020-1033. doi: 10.1080/10428194.2021.2010068. Epub 2021 Dec 2. PMID: 34852713

Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma.

Pan D, Richter J. Curr Hematol Malig Rep. 2024 Aug 15. doi: 10.1007/s11899-024-00740-z. Online ahead of print. PMID: 39145912

Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myeloma.

Avigan ZM, Arinsburg S, **Pan D**, Mark T, Fausel C, Bubalo J, Milkovich G, Chari A, Richter J. Bone Marrow Transplant. 2024 Oct;59(10):1440-1448. doi: 10.1038/s41409-024-02385-1. Epub 2024 Jul 31. PMID: 39085373

Outcomes with panobinostat in heavily pretreated multiple myeloma patients.

Pan D, **Mouhieddine TH**, Upadhyay R, Casasanta N, Lee A, Zubizarreta N, Moshier E, Richter J. Semin Oncol. 2023 Feb-Apr;50(1-2):40-48. doi: 10.1053/j.seminoncol.2023.03.006. Epub 2023 Mar 24. PMID: 37005144

Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma.

Mouhieddine TH, Van Oekelen O, Melnekoff DT, Li J, Ghodke-Puranik Y, **Lancman G**, **Thibaud S**, **Pan D**, **Rajeeve S**, Agte S, Aleman A, **Sanchez L**, Richard S, Rossi A, Richter J, Cho HJ, Rodriguez C, Lagana A, Moshier E, Chari A, Jagannath S, Parekh S. Blood Adv. 2023 Mar 28;7(6):1056-1064. doi: 10.1182/bloodadvances.2022007923. PMID: 36018226

Diagnostic and Practical Challenges in Applying National Comprehensive Cancer Network Guidelines for Suspected Pathogenic TP53 Mosaicism.

Nathan DI, Brander T, Gold J, Paul D, Klein P, Cheng K, Liu JM, Marcellino BK. JCO Precis Oncol. 2024 Jul;8: e2400006. doi: 10.1200/PO.24.00006. PMID: 38991177



Clonal hematopoiesis and inflammation: A review of mechanisms and clinical implications.

Nathan DI, Dougherty M, Bhatta M, Mascarenhas J, Marcellino BK. Crit Rev Oncol Hematol. 2023 Dec;192:104187. doi: 10.1016/j.critrevonc.2023.104187. Epub 2023 Oct 23.
PMID: 37879493

Oral Decitabine/Cedazuridine Is an Effective Ambulatory Therapy for Patients With Myelofibrosis Refractory to JAK2 Inhibitor Therapy.

Handa S, Sivakumar G, **Srisuwananukorn A**, Dueck A, Tremblay D, Mascarenhas JO, Ginzburg Y, Kremianskaya M, Hoffman R. Clin Lymphoma Myeloma Leuk. 2024 Sep;24(9):e314-e319. doi: 10.1016/j.clml.2024.05.012. Epub 2024 May 14.
PMID: 38839448

Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy.

Handa S, Lee JO, Derkach A, Stone RM, Saven A, Altman JK, Grever MR, Rai KR, Shukla M, Vemuri S, Montoya S, Taylor J, Abdel-Wahab O, Tallman MS, Park JH. Blood. 2022 Dec 22;140(25):2663-2671. doi: 10.1182/blood.2022016183.
PMID: 35930750

Obstetric and perioperative management of patients with factor XI deficiency: a retrospective observational study.

Handa S, Sterpi M, Sacchi De Camargo Correia G, Frankel DS, Beilin Y, Cytryn L, Hawkins K, Frankel E. Blood Adv. 2023 May 23;7(10):1967-1975. doi: 10.1182/bloodadvances.2022008648.
PMID: 36521104

A Review of the Pathophysiological Mechanisms Underlying Castration-resistant Prostate Cancer.

Crowley F, Sterpi M, Buckley C, Margetich L, **Handa S**, Dovey Z. Res Rep Urol. 2021 Jun 30;13:457-472. doi: 10.2147/RRU.S264722. eCollection 2021.
PMID: 34235102

Optimizing care in early phase cancer trials: The role of palliative care.

Crowley F, Sheppard R, Lehrman S, Easton E, Marron TU, Doroshov D, Afezolli D. Cancer Treat Rev. 2024 Jul;128:102767. doi: 10.1016/j.ctrv.2024.102767. Epub 2024 May 19.
PMID: 38776612



Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1/programmed death ligand 1 blockade.

Miller EJ, Rose TL, Maughan BL, Milowsky MI, Bilen MA, Carthon BC, Gao X, Rapisuwon S, Zhao Q, Yu M, Agarwal N, Galsky MD. Cancer. 2024 May 1;130(9):1642-1649. doi: 10.1002/cncr.35179. Epub 2024 Jan 5.
PMID: 38180804

Precision Medicine in Urothelial Carcinoma: Current Markers to Guide Treatment and Promising Future Directions.

Miller EJ, Galsky MD. Curr Treat Options Oncol. 2023 Dec;24(12):1870-1888. doi: 10.1007/s11864-023-01151-7. Epub 2023 Dec 12.
PMID: 38085403

Antitumor immunity as the basis for durable disease-free treatment-free survival in patients with metastatic urothelial cancer.

Anker J, Pal SK, Kim-Schulze S, Wang H, Halperin R, Uzilov A, Imai N, Eikawa S, Saito T, Sebra R, Hahn NM, Patel M, Qi J, Xie H, Bhardwaj N, Gnjjatic S, Galsky MD. J Immunother Cancer. 2023 Aug;11(8):e007613. doi: 10.1136/jitc-2023-007613.
PMID: 37607770

Advancements in Urothelial Cancer Care: Optimizing Treatment for Your Patient.

Hemenway G, **Anker JF**, Riviere P, Rose BS, Galsky MD, Ghatalia P. Am Soc Clin Oncol Educ Book. 2024 Jun;44(3):e432054. doi: 10.1200/EDBK_432054.
PMID: 38771987

Independent expansion, selection and hypervariability of the *TBC1D3* gene family in humans.

Guitart X, Porubsky D, Yoo D, **Dougherty ML**, Dishuck P, Munson KM, Lewis AP, Hoekzema K, Knuth J, Chang S, Pastinen T, Eichler EE. Genome Res. 2024 Aug 6;gr.279299.124. doi: 10.1101/gr.279299.124. Online ahead of print.
PMID: 39107043

What are the future prospects for polycythemia vera pharmacotherapies for patients with hydroxyurea resistance?

Metzger M, Mascarenhas J. Expert Opin Pharmacother. 2024 Aug;25(12):1585-1590. doi: 10.1080/14656566.2024.2396029. Epub 2024 Aug 26.
PMID: 39169882

Anagrelide for platelet-directed cytoreduction in polycythemia vera: Insights into utility and safety outcomes from a large multi-center database.

Rippel N, Tremblay D, Zubizarreta N, Podoltsev N, Gotlib J, Heaney M, Kuykendall A, O'Connell C, Shammo JM, Fleischman A, Kremyanskaya M, Hoffman R, Mesa R, Yacoub A, Mascarenhas J. Leuk Res. 2022 Aug;119:106903. doi: 10.1016/j.leukres.2022.106903. Epub 2022 Jun 16.
PMID: 35717689



Contemporary Risk Stratification and Treatment of Chronic Myelomonocytic Leukemia.
Tremblay D, **Rippel N**, Feld J, El Jamal SM, Mascarenhas J. Oncologist. 2021
May;26(5):406-421. doi: 10.1002/onco.13769. Epub 2021 Apr 21.
PMID: 33792103

Continued Success of Venetoclax in t(11;14) Multiple Myeloma Despite Negative Trials.
Avigan ZM, Joshua Richter Md. Oncology (Williston Park). 2024 Jun 10;38(6):239-241.
doi: 10.46883/2024.25921023.
PMID: 38899981

Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia.
Fruchtman H, **Avigan ZM**, **Waksal JA**, Brennan N, Mascarenhas JO. Leukemia. 2024
May;38(5):927-935. doi: 10.1038/s41375-024-02246-2. Epub 2024 Apr 10.
PMID: 38600315

Direct oral anticoagulants versus warfarin in patients with single antibody-positive anti-phospholipid syndrome.
Liu A, **Rupani KV**, Naymagon L. Eur J Haematol. 2022 Jul;109(1):69-74. doi:
10.1111/ejh.13770. Epub 2022 Apr 5.
PMID: 35305281

GLP-1 receptor agonist as an effective treatment for breast cancer-related lymphedema: a case report.
Crowley F, Brown S, Gallagher EJ, Dayan JH. Front Oncol. 2024 Apr 18;14:1392375.
doi: 10.3389/fonc.2024.1392375. eCollection 2024.
PMID: 38699640

Adherence to NCCN Genetic Testing Guidelines in Pancreatic Cancer and Impact on Treatment.
Crowley F, Gandhi S, **Rudshteyn M**, Sehmbhi M, Cohen DJ. Oncologist. 2023 Jun
2;28(6):486-493. doi: 10.1093/oncolo/oyad044.
PMID: 36933202

Prostate cancer in transgender women: considerations for screening, diagnosis and management.
Crowley F, Mihalopoulos M, Gaglani S, Tewari AK, Tsao CK, Djordjevic M, Kyprianou N, Purohit RS, Lundon DJ. Br J Cancer. 2023 Jan;128(2):177-189. doi:
10.1038/s41416-022-01989-y. Epub 2022 Oct 19.
PMID: 36261584

Ven the dose matters: Venetoclax dosing in the frontline treatment of AML.
Sastow D, **Levavi H**, Wagner N, Pratz K, Tremblay D. Blood Rev. 2024 Aug
29:101238. doi: 10.1016/j.blre.2024.101238. Online ahead of print.
PMID: 39217050